Literature DB >> 10383924

Characterization of human small intestinal cytochromes P-450.

Q Y Zhang1, D Dunbar, A Ostrowska, S Zeisloft, J Yang, L S Kaminsky.   

Abstract

Human small intestine epithelial cells (enterocytes) provide the first site for cytochrome P-450 (CYP)-catalyzed metabolism of orally ingested xenobiotics. The CYP composition of enterocytes could thus affect the potential toxicity or therapeutic efficacy of xenobiotics by modifying systemic uptake. We have characterized human enterocyte CYP composition to enable assessment of its functional roles. An isolation method for enterocytes from human small intestine was developed using EDTA buffer-mediated elution. Villous enterocytes were isolated in high yield, separated from crypt cells. Reverse transcriptase-polymerase chain reaction of total RNA from enterocytes revealed that CYP1A1, 1B1, 2C, 2D6, 2E1, 3A4, and 3A5 mRNA were expressed, but only CYP2C and 3A4 were detectable by Western immunoblotting in enterocyte microsomes from 10 human small intestines, whereas CYP1A1 was weakly detectable in two of eight intestines tested. Microsomal protein content decreased markedly along the small intestine from the duodenum to the ileum, whereas total CYP content and CYP3A4 erythromycin N-demethylase activity increased slightly in progressing from the duodenum to the jejunum and then decreased markedly toward the ileum. Levels of CYP3A4 and 2C protein did not decrease in concert as a function of length along the intestine distally. Maximal CYP content for the 10 intestines varied from 0.06 to 0.18 nmol/mg microsomal protein and maximal CYP3A4 erythromycin N-demethylase activity varied from 0.30 to 0.76 nmol/min/mg microsomal protein. In conclusion, CYP3A4 is the major form of CYP expressed in human small intestine enterocytes, CYP3A5 expression was not detected, CYP2C and, in some intestines, CYP1A1 were expressed. The highest metabolic activity occurred in the proximal intestine.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10383924

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  62 in total

1.  In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).

Authors:  X Wen; J S Wang; K T Kivistö; P J Neuvonen; J T Backman
Journal:  Br J Clin Pharmacol       Date:  2001-11       Impact factor: 4.335

Review 2.  The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?

Authors:  Margaret M Doherty; William N Charman
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 3.  Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Authors:  K Venkatakrishnan; L L von Moltke; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

4.  The impact of CYP2C8 polymorphism and grapefruit juice on the pharmacokinetics of repaglinide.

Authors:  Tanja Busk Bidstrup; Per Damkier; Anette Kristensen Olsen; Marianne Ekblom; Anders Karlsson; Kim Brøsen
Journal:  Br J Clin Pharmacol       Date:  2006-01       Impact factor: 4.335

Review 5.  Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model.

Authors:  Xianhua Cao; Seth T Gibbs; Lanyan Fang; Heather A Miller; Christopher P Landowski; Ho-Chul Shin; Hans Lennernas; Yanqiang Zhong; Gordon L Amidon; Lawrence X Yu; Duxin Sun
Journal:  Pharm Res       Date:  2006-08       Impact factor: 4.200

Review 6.  Early metabolism evaluation making traditional Chinese medicine effective and safe therapeutics.

Authors:  Yong Liu; Ling Yang
Journal:  J Zhejiang Univ Sci B       Date:  2006-02       Impact factor: 3.066

7.  Metabolic and efflux properties of Caco-2 cells stably transfected with nuclear receptors.

Authors:  Timo Korjamo; Jukka Mönkkönen; Jouko Uusitalo; Miia Turpeinen; Olavi Pelkonen; Paavo Honkakoski
Journal:  Pharm Res       Date:  2006-08-09       Impact factor: 4.200

8.  Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract.

Authors:  Mari Thörn; Niklas Finnström; Stefan Lundgren; Anders Rane; Lars Lööf
Journal:  Br J Clin Pharmacol       Date:  2005-07       Impact factor: 4.335

9.  Diabetes mellitus increases the in vivo activity of cytochrome P450 2E1 in humans.

Authors:  Zaiqi Wang; Stephen D Hall; Juan F Maya; Lang Li; Ali Asghar; J C Gorski
Journal:  Br J Clin Pharmacol       Date:  2003-01       Impact factor: 4.335

Review 10.  Overcoming pharmacologic sanctuaries.

Authors:  Theodore J Cory; Timothy W Schacker; Mario Stevenson; Courtney V Fletcher
Journal:  Curr Opin HIV AIDS       Date:  2013-05       Impact factor: 4.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.